Key result
Elevated discharge levels of both BNP and GDF-15 were associated with an over four-fold increased risk of 2-year mortality in acute heart failure patients (HR 4.33; 95% CI 2.07-9.06).
Why the study?
Do elevated plasma GDF-15 and BNP levels at discharge predict 2-year all-cause mortality in patients with acute heart failure?
Cohort (n=158)
Do elevated plasma GDF-15 and BNP levels at discharge predict 2-year all-cause mortality in patients with acute heart failure?
Hazard Ratio: 4.33 (95% CI 2.07–9.06)
Elevated GDF-15 and BNP at discharge provide incremental prognostic information, increasing the 2-year mortality risk over four-fold in acute heart failure patients.
No takes yet. Share an insight, caveat, or question.
May aid discharge risk stratification in acute HF; extends biomarker data but remains hypothesis-generating pending prospective validation.
Bettencourt et al. (2018) conducted a cohort in Acute heart failure (n=158). Elevated discharge BNP and GDF-15 (above mean) vs. Both BNP and GDF-15 below mean was evaluated on All-cause mortality (HR 4.33, 95% CI 2.07-9.06). Elevated discharge levels of both BNP and GDF-15 were associated with an over four-fold increased risk of 2-year mortality in acute heart failure patients (HR 4.33; 95% CI 2.07-9.06).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: